During the study, treatment is given in the usual way, while doctors also review how the medicine is processed in the body, possible inherited differences that may affect treatment, and other medicines that may interact with cabozantinib. Based on this review, treatment suggestions are provided to the cancer doctors. The study then looks at how often treatment has to be interrupted because of side effects. The study is expected to continue for several years.

People in the study are assigned by chance to one of the two treatment groups, and neither the study team nor the participants know which treatment is being given. The treatment is taken as tablets over time, with regular study visits during the trial. During these visits, the study team checks for side effects and overall health, and asks about symptoms and daily well-being.

The trial is looking at adults with advanced kidney cancer who have already received treatment with PD-1/L1 and VEGF-TKI medicines, either one after the other or together. PD-1/L1 and VEGF-TKI are types of cancer medicines that act in different ways to slow tumor growth. The study follows participants while they receive treatment and for some time afterward to understand the effects of the medicine combination over time.

The treatments being studied include belzutifan, which is taken as an oral film-coated tablet, and lenvatinib, which is taken as an oral capsule. Participants in the study will continue their current treatment regimen to monitor how the medications work over a longer period of time. The study will track overall survival, which refers to the length of time patients remain alive, and monitor any adverse events, which are side effects or unexpected medical problems that may occur during the treatment.

The purpose of this study is to compare how well the combination of belzutifan and zanzalintinib works against cabozantinib in treating advanced kidney cancer. The study will look at how long people live without their cancer getting worse and how long they live overall. The study will also measure how many people respond to treatment, meaning their cancer shrinks or disappears, and how long that response lasts.

During the study, people will be randomly assigned to receive either the combination treatment or cabozantinib alone. The study will track any unwanted effects that occur and whether people need to stop treatment because of these effects. The study will also measure quality of life and how well people are able to carry out daily activities using questionnaires that ask about physical health, ability to perform usual activities, and symptoms related to kidney cancer. The study will continue to follow people over time to gather information about how the treatments affect their cancer and overall health.

During the study, participants will be randomly assigned to receive either the combination of XL092 and nivolumab, or sunitinib alone. The treatment may continue for up to 252 weeks (about 5 years). Regular medical examinations and scans will be performed to monitor how well the treatment is working and check for any side effects. The study will measure how long participants live without their cancer getting worse and track their overall survival time.

Participants may receive PF-08634404 through an intravenous method, which involves delivering the medicine directly into a vein. Depending on the assigned group, the treatment may also include ipilimumab, given by intravenous use, or axitinib, which is taken as an oral medication by mouth. The study involves testing these different combinations to see how well they work against the cancer and to identify the best amount of medicine to use.

During the study, participants may receive PTT-4256 as an oral tablet. If the combination treatment is used, nivolumab will be administered through an infusion, which is a method of delivering medication directly into a vein. The research involves observing how the body processes these drugs and monitoring for any side effects to determine the best possible dose for patients.

The purpose of this study is to investigate the cardiovascular side effects of immune checkpoint inhibitors, which means looking at how these cancer treatments might affect the heart and blood vessels. The study will monitor patients who are receiving these treatments as part of their regular cancer care. During the study, doctors will check for various heart-related problems that might develop or get worse during treatment. The treatment period with these medicines can last up to twelve months.

The main focus of the study is to track serious heart-related events, including death from heart problems, heart attacks, strokes, chest pain that requires hospital care or urgent treatment to restore blood flow to the heart, and hospital stays due to heart failure (when the heart cannot pump blood well enough). The study will also look at other heart and blood vessel problems such as new or worsening high blood pressure, irregular heartbeats, blood clots in the veins, and other heart-related issues that require hospital admission. This research aims to better understand how these cancer treatments affect the heart and blood vessels so that doctors can better monitor and care for patients receiving these medicines.

Patients taking part in this study must already be taking cabozantinib at a stable dose of either 40 mg or 20 mg once daily for at least four weeks. The study will compare different ways of taking the medicine. Instead of taking a lower dose every day on an empty stomach, patients will take a higher dose of 60 mg with a standard breakfast but will skip taking the medicine on some days. For example, one pattern involves taking the medicine for two days and then skipping one day, while another pattern involves taking it for one day and then skipping two days. During the study, blood samples will be taken to measure the amount of cabozantinib in the blood over a period of 72 hours after taking the medicine.

The study will look at whether the amount of medicine in the blood is similar between the different dosing patterns by measuring the area under the concentration-time curve and the blood trough concentration, which is the level of medicine in the blood just before the next dose. The study will also collect information about side effects, hospital visits, medication use, and quality of life using questionnaires. Patients will be asked whether they would prefer to continue taking cabozantinib with food or return to taking it on an empty stomach. The study is expected to start enrolling patients in October 2025 and finish in October 2027.

The purpose of this research is to determine whether the amount of Rubidium-82 absorbed by the tumor can accurately indicate how aggressive the cancer is. During the study, participants will receive a single injection of Rubidium Chloride through a vein (given intravenously) before undergoing the PET scan. The maximum amount of radioactive substance used will be 2300 MBq (megabecquerels, a measure of radioactivity).

The scanning procedure will take place before patients undergo their planned surgery for tumor removal. The images obtained from the PET scan will be compared with the actual tumor tissue examined after surgery to verify if this new imaging method can accurately predict the aggressiveness of kidney tumors. This information could help doctors make better treatment decisions for future patients with kidney cancer.

The study is divided into two phases. The first phase will focus on finding the right dose of the medications and checking their safety. The second phase will look at how effective the treatment is in fighting the cancer. The medications are taken by mouth in the form of tablets. Patients will be monitored for any side effects and how their cancer responds to the treatment.

Throughout the study, doctors will track how the tumors respond to treatment, how long the response lasts, and how long patients survive without their cancer getting worse. They will also monitor the overall survival of patients and look for any benefits from the treatment. Regular medical check-ups and tests will be performed to ensure patient safety and evaluate the treatment’s effectiveness.

The purpose of the study is to evaluate how digital monitoring of symptoms reported by patients can help in managing their treatment. This involves patients using digital tools to report their symptoms, which can then be used to adjust their treatment plan. The study will observe how this approach affects the management of the treatment during the first three months.

Participants in the study will receive the combined treatment of Cabozantinib and Nivolumab. They will be asked to report their symptoms digitally on a regular basis. The study will monitor how these reports can lead to changes in treatment, such as scheduling earlier consultations or making adjustments to the medication. The study aims to improve the way treatments are managed for patients with advanced clear-cell renal carcinoma.

The purpose of this study is to evaluate how well the combination of Pembrolizumab and Enfortumab Vedotin works in treating these specific types of kidney cancer. Participants in the study will receive these medications through an infusion, which is a way of delivering the treatment directly into the bloodstream. The study will last for a period of up to 36 months, during which the effectiveness of the treatment will be monitored. Some participants may receive a placebo, which is a substance with no active medication, to compare the results.

The main goal of the study is to determine the Objective Response Rate (ORR), which measures how well the cancer responds to the treatment. Secondary goals include assessing progression-free survival (PFS), which is the length of time during and after treatment that the cancer does not get worse, and overall survival (OS), which is the length of time participants live after starting the treatment. The study will also look at how well participants tolerate the treatment. The trial is expected to continue until December 2029.

The purpose of the study is to assess the safety and effectiveness of AL8326 in patients who need a second or later line of treatment for Small Cell Lung Cancer. This includes patients whose cancer has spread to the brain, as long as the brain metastasis is controlled and not causing active bleeding. The study aims to find the best dose of the medication that balances effectiveness and safety.

Participants in the study will receive AL8326 and will be monitored over a period of time to observe how well the drug works and to check for any side effects. Some participants may receive a placebo for comparison. The study will help determine the optimal dose and gather information on how the drug affects the body, which will be useful for future treatments of Small Cell Lung Cancer.

The purpose of this study is to find the best dose of Fianlimab and the best time to perform a special type of imaging called PET scan to see how the treatment is working. A PET scan is a test that helps doctors see how organs and tissues inside the body are functioning. The study will also look at how safe Fianlimab is for patients. Participants will receive the treatment and undergo PET scans before and during their treatment with Cemiplimab, with or without chemotherapy. The study will help researchers understand how the treatment affects the body and how well it works against the cancer.

Throughout the study, patients will be monitored closely to ensure their safety and to observe any changes in their condition. The study aims to provide valuable information that could lead to better treatment options for people with advanced solid cancers. By understanding how these medications work together, researchers hope to improve outcomes for patients facing these challenging diseases.

The purpose of this study is to compare the effects of continuing standard immunotherapy with a reduced dose of the same treatment. The medications being studied include Pembrolizumab, Durvalumab, Avelumab, Nivolumab, Dostarlimab, Atezolizumab, and Cemiplimab. These medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. Some patients will receive the standard dose of these medications, while others will receive a reduced dose every three months.

The study will last for up to three years, during which time patients will continue to receive their assigned treatment. The main goal is to see if the reduced dose is as effective as the standard dose in keeping the cancer from getting worse. Patients will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study will also look at other factors, such as the quality of life and any side effects experienced by the patients. This research aims to find the best way to use immunotherapy to treat cancer effectively while minimizing side effects.

The purpose of the study is to evaluate how effective and safe Cabozantinib is when used as a second treatment option for this type of kidney cancer. Participants in the study will take Cabozantinib tablets by mouth. The study will observe how the cancer responds to the treatment over time. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active substance. The study will last for a period of time, during which participants will have regular check-ups to monitor their health and the progress of the treatment.

Throughout the study, the response of the cancer to Cabozantinib will be assessed using specific criteria to determine if the treatment is working. The study aims to provide valuable information on whether Cabozantinib can be a beneficial treatment option for patients with advanced Renal Cell Carcinoma who have not had success with their first line of treatment. Participants will be closely monitored to ensure their safety and to gather data on the effectiveness of the treatment.

Participants in the study will receive a reduced dose of nivolumab, administered through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the levels of the drug in the body to ensure they remain effective while using a lower dose. This approach aims to maintain the benefits of the treatment while potentially reducing side effects and costs.

The study will take place over a period of time, with regular assessments to check the drug levels and monitor any side effects. The goal is to determine if the reduced dose can maintain the same level of effectiveness as the higher dose previously used. This research could lead to improved treatment strategies for patients with melanoma and renal cell carcinoma, making their therapy more manageable and cost-effective.

The purpose of the study is to analyze how well patients respond to these treatments and how long they can continue the treatment without it failing. The study will follow participants over a period of time to observe their response to the treatment. Participants will receive either the study medication or a placebo, and their health will be monitored regularly to assess the effectiveness and safety of the treatment. The study aims to gather information on the overall response rate, which includes both complete and partial responses to the treatment, as well as the time it takes for the treatment to no longer be effective.

Throughout the study, participants will undergo various assessments to monitor their health and the progression of their cancer. These assessments may include imaging tests and laboratory tests to evaluate the impact of the treatment on the cancer and the patient’s overall health. The study will also collect information on the duration of response to the treatment, the rate of disease control, and any side effects experienced by the participants. This information will help researchers understand the potential benefits and risks of the treatment strategy for patients with metastatic non-clear cell kidney cancer.

The purpose of the study is to evaluate how well the combination of atezolizumab and cabozantinib works compared to cabozantinib alone. Participants will receive either the combination treatment or cabozantinib by itself. The study will monitor the participants over a period of time to assess the progression of the cancer and overall survival. The trial will also look at the side effects of the treatments and how they affect the participants’ health.

Participants in the study will receive the treatments either as a film-coated tablet taken by mouth or as a solution for infusion, which is administered through a vein. The study aims to provide valuable information on the potential benefits of combining atezolizumab with cabozantinib for patients with advanced kidney cancer. The results could help improve treatment options for those affected by this disease.

The purpose of this study is to understand which form of Pembrolizumab patients prefer. Participants will receive both forms of the medication during the study. They will be asked to share their preferences and satisfaction with each method of receiving the treatment. The study will also monitor any side effects that participants may experience. This information will help doctors understand which method of treatment is more comfortable and preferable for patients.

Throughout the study, participants will be asked to complete questionnaires about their experiences and preferences. The study aims to gather information on how patients feel about the convenience and comfort of each treatment method. This will help improve the way cancer treatments are given in the future, making them more patient-friendly. The study is expected to continue until 2026, providing valuable insights into patient preferences for cancer treatment administration.

The purpose of the study is to understand how well these treatments work in patients who have not received any previous treatment for their advanced kidney cancer and have certain risk factors. Participants will receive either the combination of Nivolumab and Ipilimumab or Nivolumab alone. Some participants may receive a placebo. The study will monitor the progress of the disease and the response to the treatment over time.

Throughout the study, participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of time, during which the health and response of the participants will be closely observed. The goal is to determine which treatment option is more effective in managing the cancer and improving the patients’ health outcomes.

Participants in the study will receive the treatment combination over a period of time, with INCB099280 being taken orally and Ipilimumab administered through an intravenous infusion. The study will monitor the participants for any side effects or reactions to the treatment. The goal is to find the right dose that is both safe and effective for patients. The study will also compare the effects of the treatment combination to a placebo to better understand its impact.

Throughout the study, participants will have regular check-ups and tests to assess their health and the progress of their treatment. These tests will help researchers understand how the treatment affects the body and whether it helps control the growth of the tumors. The study is expected to continue for several years, allowing researchers to gather comprehensive data on the treatment’s safety and effectiveness.

The purpose of the study is to assess the safety and tolerability of these treatments, which means checking for any side effects and determining how well patients can handle the medications. The study will also gather preliminary information on how effective these treatments are in managing the disease. Participants will receive the medications in different doses and combinations to find the most effective and safest way to use them. The trial will also explore if a more convenient dosing schedule can be established for patients.

Throughout the study, participants will be monitored for any adverse events, which are unwanted effects that may occur during treatment. The trial will also measure how the body processes the medications, including how long they stay in the body and how they are eliminated. The study will continue until the estimated end date in 2026, with the goal of providing valuable information on the potential benefits of Relatlimab and Nivolumab for treating advanced solid tumors.

The purpose of the study is to assess the safety and effectiveness of these treatment combinations. The study is divided into two phases. The first phase focuses on understanding the safety and tolerability of the treatments, which means checking how well patients can handle the medications and identifying any side effects. The second phase evaluates how well the treatments work in reducing the size of the cancer or stopping its growth. This is done by observing the response of the cancer to the treatments over time.

Participants in the study will receive one or more of the medications, or a placebo, and will be monitored for any side effects and changes in their cancer. The study aims to find the best dose and combination of these treatments to help manage renal cell carcinoma effectively. The trial will continue until the estimated end date in 2025, with ongoing assessments to ensure the safety and well-being of the participants.

The purpose of this study is to compare the effectiveness of V940 plus Pembrolizumab against a placebo plus Pembrolizumab in preventing the return of cancer after surgery. Participants will receive these treatments through injections or infusions over a period of time. The study will monitor how long participants remain free of cancer and will also track any side effects they may experience. The trial aims to provide valuable information on whether this combination of treatments can improve outcomes for patients with RCC.

Participants in the study will be closely monitored by healthcare professionals throughout the trial. The study will assess how well the treatments work in keeping the cancer from coming back and will also look at the overall survival of participants. The trial is expected to continue for several years to gather comprehensive data on the long-term effects and benefits of the treatments being tested.

The purpose of this study is to compare how well these two treatment approaches work in people whose cancer has progressed after receiving a specific type of immunotherapy (anti-PD-1/L1 therapy). The study will measure which treatment is better at stopping the cancer from growing and helping patients live longer.

During the study, participants will be randomly assigned to receive either the combination of belzutifan and lenvatinib or cabozantinib alone. The treatment will continue for up to 46 months, as long as it is working and the side effects are manageable. Throughout the study, doctors will regularly check the participants’ health and monitor how their cancer responds to the treatment.

The purpose of the study is to determine which treatment combination is more effective in improving survival rates and delaying the progression of the disease. The study will also look at how these treatments affect patients’ quality of life and any side effects they may experience. Participants will be randomly assigned to receive one of the treatment combinations, and some may receive a placebo. The trial will monitor patients over a period to assess the outcomes of the treatments.

Throughout the study, patients will have regular check-ups and assessments to track their health and the effectiveness of the treatment. The trial aims to provide valuable information that could help improve treatment strategies for people with metastatic renal cell carcinoma in the future.

The purpose of the study is to evaluate how well these combinations work and how safe they are for patients. Participants will receive these medications through an intravenous infusion, which means the medicine is given directly into a vein. The study will compare different groups of patients receiving different combinations of these drugs. One group will receive Tobemstomig and Axitinib, another will receive Tiragolumab, Tobemstomig, and Axitinib, and a control group will receive Pembrolizumab and Axitinib. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual drugs.

The study will take place over a period of up to 24 months, during which participants will be monitored for any changes in their condition and any side effects they may experience. The goal is to determine which combination of treatments is most effective in slowing down the progression of the cancer and to assess the overall safety of these treatments. Participants will be closely observed by medical professionals throughout the study to ensure their well-being and to gather important data on the treatments being tested.

The purpose of the study is to evaluate the safety and potential benefits of these medications when used together. Participants will receive the treatment and be monitored for any side effects and how well the cancer responds to the treatment. The study will help determine the best dose of MEDI5752 to use in future research. The treatment with MEDI5752 is given through an infusion, which means it is administered directly into the bloodstream, while lenvatinib and axitinib are taken orally as capsules.

Throughout the study, participants will have regular check-ups to monitor their health and the progress of the cancer. This includes various tests and assessments to ensure the treatment is working as intended and to identify any potential side effects. The study aims to provide valuable information that could lead to new treatment options for people with advanced kidney cancer.

Participants in the study will receive either Belzutifan alone or a combination of Belzutifan and Palbociclib. The study will be conducted in two parts. In the first part, researchers will focus on the safety and tolerability of the treatments. In the second part, they will evaluate how well the cancer responds to the treatments. The study will monitor participants for any side effects and how the cancer progresses over time.

This trial aims to provide valuable information on the effectiveness of these treatments for advanced renal cell carcinoma, potentially leading to better treatment options for patients in the future. The study is expected to continue until 2027, with recruitment starting in 2024.

The goal of this study is to continue providing the treatment to patients who have already participated in earlier phases of similar studies but still need ongoing therapy since they cannot access these medicines locally. This means the therapy will continue for patients who are still benefiting from it according to assessments by their doctors.

The study does not provide detailed procedures but involves using these medicines to see if the patients continue to respond positively to the treatment therapies. This ongoing treatment will allow the observation of the treatments’ effects over a longer period and help determine the best use of these drugs in managing cancer. Some patients might be given a placebo, which is a substance with no therapeutic effect used in trials to test the effectiveness of another drug.

The purpose of the study is to explore how effective these medications are when used together before surgery to remove the cancer. This approach is known as “neoadjuvant” therapy, which means treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery. The study will also look at the safety of using these two medications together and monitor any side effects that may occur.

Participants in the study will receive the medications for a period of up to three months. During this time, doctors will closely monitor the patients to see how the cancer responds to the treatment and to ensure the safety of the participants. After the treatment period, patients will continue to be followed for a longer time to check on their health and to see if the cancer returns or spreads. The study aims to provide valuable information on the potential benefits of using axitinib and avelumab together in treating renal cell carcinoma.

The purpose of the study is to evaluate the safety and effectiveness of these treatment combinations. Participants will receive different combinations of the medications, which may be given as a solution for infusion (a liquid given through a vein) or as capsules or tablets taken by mouth. The study will monitor participants for any side effects and measure how well the cancer responds to the treatments.

The study is divided into two phases. The first phase focuses on assessing the safety and tolerability of the treatment combinations. The second phase evaluates the effectiveness of the treatments by looking at how the cancer responds. Participants will be closely monitored throughout the study to ensure their safety and to gather information on how well the treatments work against renal cell carcinoma.

The purpose of the study is to explore how well these medications work together in treating the mentioned cancers. The study is divided into different phases. Initially, the focus is on understanding the safety and how well patients tolerate the combination of BGB-A425 with Tislelizumab. Later, the study will also look at the combination of BGB-A425 and LBL-007 with Tislelizumab, as well as LBL-007 with Tislelizumab. The study aims to find the best dose that patients can handle without severe side effects.

Throughout the study, researchers will monitor patients for any side effects and measure how the cancer responds to the treatment. The study will also assess how the body processes these medications. This research is important for developing new treatment options for patients with these types of advanced cancers.

Participants in the study will receive either pembrolizumab or a placebo. The study will monitor how long participants remain free of cancer after treatment, which is referred to as disease-free survival. Additionally, the study will look at overall survival, which measures how long participants live after starting the treatment. The study will also track any side effects experienced by participants and whether any participants stop the treatment due to side effects.

The study will take place over a period of time, with participants receiving treatment and being monitored for changes in their health. Regular assessments will be conducted to check for any recurrence of cancer and to evaluate the overall health and quality of life of the participants. The study aims to provide valuable information on the potential benefits of pembrolizumab for patients with renal cell carcinoma following surgery.

Participants in the study will receive nivolumab in different forms, including subcutaneous injections and intravenous infusions. The study will observe how the medication moves through the body and how it is absorbed, distributed, and eliminated. This will help researchers understand the best way to administer nivolumab for treating these cancers. The study will also monitor for any side effects or reactions to the medication, including any allergic reactions or the development of antibodies against nivolumab.

The study is expected to continue until August 2025. During this time, participants will receive regular doses of the medication and will be closely monitored by the research team. The information gathered from this study will contribute to the understanding of nivolumab’s effectiveness and safety in treating various types of cancer.

Participants in the study will receive both Pembrolizumab and Lenvatinib as their first treatment for advanced or metastatic Non-clear Cell Renal Cell Carcinoma. The study will monitor how the cancer responds to the treatment over time. This includes checking if the cancer shrinks or disappears and how long any positive effects last. The study will also track the overall health and survival of participants, as well as any side effects they may experience from the treatment.

The trial will continue for a set period, during which participants will regularly visit the study site for treatment and assessments. These assessments will help researchers understand the effectiveness and safety of the combination of Pembrolizumab and Lenvatinib in treating this type of kidney cancer. The information gathered from this study may contribute to future treatment options for patients with Non-clear Cell Renal Cell Carcinoma.

The purpose of the study is to determine which combination of these medications can help patients live longer without their cancer getting worse. Participants will be randomly assigned to receive one of the treatment combinations. Some participants will receive Pembrolizumab with Belzutifan and Lenvatinib, others will receive MK-1308A with Lenvatinib, and another group will receive Pembrolizumab with Lenvatinib. There is also a possibility of receiving a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The study will monitor participants over a period to assess how well the treatments work and to check for any side effects. The goal is to find the most effective treatment combination that can help manage the disease and improve the quality of life for those with advanced clear cell renal cell carcinoma. Participants will receive regular check-ups and assessments to track their progress throughout the study.

The purpose of the study is to compare the combination of Tivozanib and Nivolumab with Tivozanib alone in patients whose cancer has progressed after one or two previous treatments, including a type of treatment called an immune checkpoint inhibitor. This study will help determine if the combination of these medications can help patients live longer without their cancer getting worse.

Participants in the study will receive either the combination of Tivozanib and Nivolumab or Tivozanib alone. The study will monitor the participants over a period to see how their cancer responds to the treatment. The study will also assess the safety and any side effects of the treatments. The results will provide valuable information on the potential benefits of combining these medications for treating Renal Cell Carcinoma.